Welcome to LookChem.com Sign In|Join Free

CAS

  • or

29390-66-7

Post Buying Request

29390-66-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

29390-66-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 29390-66-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,9,3,9 and 0 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 29390-66:
(7*2)+(6*9)+(5*3)+(4*9)+(3*0)+(2*6)+(1*6)=137
137 % 10 = 7
So 29390-66-7 is a valid CAS Registry Number.

29390-66-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name MONO-6-IODO-6-DEOXY-BETA-CYCLODEXTRIN

1.2 Other means of identification

Product number -
Other names MONO-6-IODO-6-DEOXY-BETA-CYCLODEXTRIN

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:29390-66-7 SDS

29390-66-7Relevant articles and documents

Excimer formation in inclusion complexes of modified cyclodextrins

Ueno,Moriwaki,Osa,et al.

, p. 1571 - 1578 (1987)

-

Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a mannosylated cyclodextrin carrier

Rodriguez-Lavado, Julio,De La Mata, Mario,Jimenez-Blanco, Jose L.,Garcia-Moreno, M. Isabel,Benito, Juan M.,Diaz-Quintana, Antonio,Sanchez-Alcazar, Jose A.,Higaki, Katsumi,Nanba, Eiji,Ohno, Kousaku,Suzuki, Yoshiyuki,Ortiz Mellet, Carmen,Garcia Fernandez, Jose M.

, p. 2289 - 2301 (2014)

Gaucher disease (GD) is a rare monogenetic disorder leading to dysfunction of acid β-glucosidase (β-glucocerebrosidase; GCase) and accumulation of glucosylceramide in lysosomes, especially in macrophages (Gaucher cells). Many of the mutations at the origin of GD do not impair the catalytic activity of GCase, but cause misfolding and subsequent degradation by the quality control system at the endoplasmic reticulum. Pharmacological chaperones (PCs) capable of restoring the correct folding and trafficking of the endogenous mutant enzyme represent promising alternatives to the currently available enzyme replacement and substrate reduction therapies (ERT and SRT, respectively), but unfavorable biodistribution and potential side-effects remain important issues. We have now designed a strategy to enhance the controlled delivery of PCs to macrophages that exploit the formation of ternary complexes between the PC, a trivalent mannosylated β-cyclodextrin (βCD) conjugate and the macrophage mannose receptor (MMR). First, PC candidates with appropriate relative avidities towards the βCD cavity and the GCase active site were selected to ensure efficient transfer of the PC cargo from the host to the GCase active site. Control experiments confirmed that the βCD carrier was selectively recognized by mannose-specific lectins and that the corresponding PC:mannosylated βCD supramolecular complex retained both the chaperoning activity, as confirmed in human GD fibroblasts, and the MMR binding ability. Finally, fluorescence microscopy techniques proved targeting and cellular uptake of the PC-loaded system in macrophages. Altogether, the results support that combined cyclodextrin encapsulation and glycotargeting may improve the efficacy of PCs for GD. This journal is

Synthesis of monocationic β-cyclodextrin derivatives

Shipilov,Kurochkina,Levina,Malenkovskaya,Grachev

, p. 290 - 295 (2017)

Reactions of 6-bromo- and 6-iodo-6-deoxy-β-cyclodextrin with organic amines of diverse nature afforded a series of monocationic derivatives with aminium groups located in the cyclodextrin scaffold on the side of the primary hydroxy groups. The structure a

COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES

-

Paragraph 0164; 0165, (2017/03/21)

The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to fo

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 29390-66-7